Teknologi pengembangan vaksin berbasis vektor adenovirus

Abstract

ABSTRACT
Vaccine manufacturing technology has developed rapidly, especially in terms of the method of delivery of antigens to the human body or vaccinated animals. One of them is the use of virus vectors. The advantage of vaccines using this technology is that they do not require additional adjuvants in administration as well as the protein sub-unit vaccine. It also has the ability to induce cellular immune responses in addition to humoral immune responses. One of the virus vectors that has been widely used is adenovirus. In one study we used the human adenovirus serotype 5 (Ad5) vector to carry the genetic material of the malaria parasite derived from a protein located on the surface of the sporozoite stage (circumsporozoite). The antigen inserted into the viral vector was the chimera of two Plasmodium vivax strains, namely VK210 and VK247. The results of immunostaining showed that the adenovirus carrying the chimera antigen can induce the expression of both proteins in HEK 293A cell culture. Thus, it can be concluded that the Ad5 vector-based vivax malaria vaccine in this study has the ability to transduce mammalian cells, which is an important requirement for further trials in experimental animals. Adenovirus has been used in human trials of the falciparum malaria vaccine as well as in several vaccine candidates for COVID-19 being developed in China and the UK.
 
keywords: viral vector, adenovirus, viral vectored vaccine, circumsporozoite